ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 254 for:    "psoriatic arthritis"

Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00451243
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : March 23, 2007
Sponsor:
Information provided by:
National Taiwan University Hospital

Brief Summary:
Psoriasis is a multifactorial cutaneous disorders which affects about 100000 patients in Taiwan. Psoriatic arthritis is also present in about 20~30 percents. Many drugs have been shown to aggravate psoriasis including drugs used in the treatment of psoriatic arthritis. On the contrary, anti-psoriatic drugs are also known to aggravate or induce psoriatic arthritis. Psoriasis and psoriatic arthritis are believed to share the same pathogenic lymphocytes, but the differential responses to drugs are intriguing. This also causes problems in the treatment of psoriasis and psoriatic arthritis. Recently different serologic markers have been found for the assessment of psoriasis and psoriatic arthritis. Recent genetic study showed a different genetic susceptibility genes. We tested the serologic responses of three new biologic drugs used in the treatment of psoriasis and psoriatic arthritis. Paired blood samples of the same patients before and after 12 weeks of treatment were used. IL6 decreased after alefacept and etanercept but was increased after efalizumab treatment without statistical significance (Paired t test: 0.3336、0.2773、0.5904)。IL-8 decreased after etanercept but increased after efalizumab and alefacept without statistical significance (Paired t test: 0.4031、0.6749、0.2998)。IL10 decreased after efalizumab and etanercept, but increased significantly after alefacept treatment (Paired t test: 0.7254、0.5123、0.0350)。None of the treatment has a significant effect on TNF-alpha. HC10 decreased after alefacept and efalizumab,but increased after etanercept treatmentwithout statistical significance (Paired t test: 0.6589、0.1576、0.1988).

Condition or disease
Psoriatic Arthritis

Study Type : Observational
Enrollment : 20 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatmen
Study Start Date : January 2005
Study Completion Date : June 2005






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of psoriasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451243


Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: TSEN-FANG Tsai TSEN-FANG Tsai

ClinicalTrials.gov Identifier: NCT00451243     History of Changes
Other Study ID Numbers: 9361701244
9361701244
First Posted: March 23, 2007    Key Record Dates
Last Update Posted: March 23, 2007
Last Verified: December 2004

Keywords provided by National Taiwan University Hospital:
psoriatic arthritis

Additional relevant MeSH terms:
Arthritis
Psoriasis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases